Novo Nordisk Submits MAA for Oral Semaglutide

Novo Nordisk has announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue tablet.

To be used as a treatment of adults with Type 2 diabetes, this once-daily oral formulation utilises Emisphere Technologies’ proprietary Eligen® SNAC Carrier Technology.

Oral semaglutide has now been submitted for regulatory approval in the US, the EU and Canada.

More About This Company

Development Update

Novo Nordisk announced the European Commission (EC) has granted marketing authorisation for Rybelsus®, (oral semaglutide),...